Nigerian Drug Anti-counterfeiting Startup, RxAll, Secures $3.5m In New Funding Round
RxAll, a startup based in the United States and Nigeria that uses deep technology to offer patients with high-quality medication, has raised $3.15 million in funding to expand into other countries and develop its technology.
This funding round combines a recently closed $2 million seed round (which was oversubscribed by $2.25 million) and a $900,000 pre-seed round raised at the end of last year. The financing was led by Launch Africa, with participation from SOSV’s HAX and Keisuke Honda’s KSK fund.
Read also:Egyptian E-health Startup Estshara Secures $500k In Seed Funding Round
With the latest funding, the company hopes to expand to an additional 14 locations before the end of the year, with a pan-African strategy in the works for next year.
Why The Investors Invested
“Launch Africa Ventures is excited to be co-leading this round of financing into a strong, experienced team at RxAll. We believe that RxAll is bridging a major gap in access to quality healthcare in Africa by pioneering a drug delivery platform to enable pharmacies and patients to buy authenticated medicines online. The ability to achieve favourable unit economics and multiple revenue streams by leveraging anti-counterfeiting mobile spectrometer technology, owning the entire drug delivery supply chain and their own payment wallet, provides a massive growth and scaling opportunity across Africa and beyond,” managing partner at Launch Africa Ventures Zachariah George said.
“We’ve been incredibly impressed by RxAll’s ability to scale and meet customer demand. In just the last year, the team has brought together world-class hard tech and operational excellence to solve pressing issues for over a million Nigerians, and we couldn’t be more excited by their vision for the broader pharmaceutical market,” Duncan Turner, general partner at SOSV and managing director of HAX said.
A Look At What The Startup Does
Founded in 2016 by Adebayo Alonge, Amy Kao and Wei Lui, RxAll’s proprietary technology, RxScanner, is a portable authenticator allowing patients to verify their medications. The RxScanner, according to the company, can determine the quality of prescription pharmaceuticals in 20 seconds and present the results in real time via mobile apps.
RxAll selects high-quality sellers for its marketplace and delivers the RxScanner to them. The machine learning model reads the sample spectra and sends test results that show the identity and quality of the sample in comparison to the reference. Sellers can be located using the filter, and once batch testing is completed, the seller can release the product into the marketplace and make it available for on-demand ordering, pick-up, and deliveries.
Commissions from deals on the marketplace are how the company makes money. With the RxScanner, it also uses a subscription model for both individual and business users.
Read also:‘Big Business and Small Business Need Each Other Now More Than Ever’
In Nigeria, the firm is presently serving ten cities and is actively validating the validity of pharmaceuticals for 1 million patients while also supporting over 2,000 hospitals and pharmacies.
RxAll drug anti-counterfeiting RxAll drug anti-counterfeiting
Charles Rapulu Udoh
Charles Rapulu Udoh is a Lagos-based lawyer who has advised startups across Africa on issues such as startup funding (Venture Capital, Debt financing, private equity, angel investing etc), taxation, strategies, etc. He also has special focus on the protection of business or brands’ intellectual property rights ( such as trademark, patent or design) across Africa and other foreign jurisdictions.
He is well versed on issues of ESG (sustainability), media and entertainment law, corporate finance and governance.
He is also an award-winning writer
